Back to top
more

Akero Therapeutics (AKRO)

(Delayed Data from NSDQ)

$29.76 USD

29.76
720,241

-1.21 (-3.91%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $29.00 -0.76 (-2.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus

by Zacks Equity Research

Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.

Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?

by Zacks Equity Research

Here is how Akero Therapeutics, Inc. (AKRO) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues

by Zacks Equity Research

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.

    Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

    by Zacks Equity Research

    Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.

    Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss

    by Zacks Equity Research

    Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.

    Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates

    by Zacks Equity Research

    Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.

    Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

    by Zacks Equity Research

    Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.

    Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates

    by Zacks Equity Research

    Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

    Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark

    by Zacks Equity Research

    Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.

    Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2

    by Zacks Equity Research

    Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.

    Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

    by Zacks Equity Research

    Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.

    Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers

    by Zacks Equity Research

    Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.

    AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

    by Zacks Equity Research

    AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.

    Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

    by Zacks Equity Research

    Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

    Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Akero Therapeutics, Inc. (AKRO) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

    Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

    by Zacks Equity Research

    Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

    Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

    by Zacks Equity Research

    Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

    Akero Therapeutics (AKRO) Up on Positive Data from NASH Study

    by Zacks Equity Research

    Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.

      Akero Therapeutics (AKRO) Up on Positive NASH Study Data

      by Zacks Equity Research

      Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.

      Cigna (CI) to Announce Q2 Earnings: Here's What to Expect

      by Zacks Equity Research

      Cigna's (CI) second-quarter results are likely to reflect higher pharmacy revenues and a growing customer base.

      Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?

      by Zacks Equity Research

      Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

      Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a Bet

      by Zacks Equity Research

      The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 91.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

      Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel

      by Zacks Equity Research

      Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.

      Can Akero Therapeutics (AKRO) Run Higher on Strong Earnings Estimate Revisions?

      by Zacks Equity Research

      Akero Therapeutics (AKRO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

      Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data

      by Zacks Equity Research

      Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.